Cargando…
Omitting ALND Is Not Safe for a Cohort of Early-Stage Breast Cancer Patients with 1–2 SLNs Macro-Metastases and Breast-Conserving Therapy: A Single-Center Retrospective Study
BACKGROUND: Omitting axillary lymph node dissection (ALND) is recommended for early-stage breast cancer patients with 1–2 sentinel lymph nodes (SLNs) macro-metastases and breast-conserving therapy. However, it is not safe for part of patients, so it is significant to find risk factors and develop a...
Autores principales: | WANG, Xiangyu, GAO, Yinqi, YANG, Xue, KONG, Xiangyi, WANG, Zixing, FANG, Yi, WANG, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548499/ https://www.ncbi.nlm.nih.gov/pubmed/33083292 http://dx.doi.org/10.18502/ijph.v49i7.3579 |
Ejemplares similares
-
Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer
por: Gherghe, M, et al.
Publicado: (2015) -
Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation
por: Zhong, Ying, et al.
Publicado: (2020) -
Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
por: Damle, Sameer, et al.
Publicado: (2009) -
The Feasibility of Omitting Postoperative Radiotherapy in Japanese Patients With Ductal Carcinoma In Situ of Breast Treated With Breast-Conserving Surgery
por: Nakashima, Akihiro, et al.
Publicado: (2023) -
Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)